Zhu Zhenggang
Department of Surgery, Shanghai Institute of Digestive Surgery, Shanghai Key Laboratory of Gastric Neoplasm, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Jan 25;21(1):7-14.
The 12th International Gastric Cancer Congress (12th IGCC ) was successfully held in Beijing, China on 20th-23rd April, 2017, which gave Chinese surgeons a great opportunity to share clinical progress and experience in the surgical treatment of gastric cancer with colleagues from different countries. At the end of 2017, this article hereby reviews briefly the achievements of surgical work of gastric cancer, which was done by our Chinese surgeons in this year. Some aspects will be reviewed, aiming at summarizing experience, affirming achievement, finding out the gap and promoting improvement in the future. These aspects include the conversion therapy for stageIIII( gastric cancer; the minimally invasive surgery for gastric cancer; the alimentary tract reconstruction after gastrectomy; enhanced recovery after radical gastrectomy and surgery quality control and patient's quality of life after surgery. In 2017, the gastric cancer surgery in China has made some new progress in many fields, and some achievements have reached or are close to international advanced level. However, looking ahead to the coming year and the future, there are still some important works to be done in the field of clinical surgery for gastric cancer in China, which include (1) strengthening big clinical data in gastric cancer collection and analysis platform construction for the promotion of scientific decision in therapeutic strategy; (2) further participating in international academic exchange and cooperation with taking advantages of our big number of gastric cancer cases, great amount of bio-tissue samples and big number of professional surgeons to actively join the international clinical research and expand our academic influence in the world;(3)developing more multicentre prospective randomized controlled trials in order to further improve the scientific significance in Chinese clinical guideline, norms and expert consensus in surgical treatment for gastric cancer; (4) further improving effectiveness of the multidisciplinary team (MDT) model in order to truly play the role of each subject in resolving some difficult cases; (5) in terms of surgical treatment for patients, it should be continue to keep going on minimally invasive operation, rational perioperative treatment, refinement technique, radical cure resection, and to further improve operation quality control system, aiming at realizing both goals simultaneously in prolonging survival time and improving quality of life for the patients with gastric cancer.
第十二届国际胃癌大会(第12届IGCC)于2017年4月20日至23日在中国北京成功举办,这为中国外科医生提供了一个与来自不同国家的同行分享胃癌外科治疗临床进展和经验的绝佳机会。2017年底,本文特此简要回顾了这一年来中国外科医生在胃癌外科工作方面所取得的成绩。将对一些方面进行回顾,旨在总结经验、肯定成绩、找出差距并推动未来改进。这些方面包括Ⅲ期胃癌的转化治疗;胃癌的微创手术;胃切除术后的消化道重建;根治性胃切除术后的加速康复以及手术质量控制和术后患者生活质量。2017年,中国的胃癌手术在许多领域取得了一些新进展,部分成果已达到或接近国际先进水平。然而,展望来年及未来,中国胃癌临床外科领域仍有一些重要工作要做,其中包括:(1)加强胃癌大临床数据收集与分析平台建设,以促进治疗策略的科学决策;(2)利用我国大量的胃癌病例、丰富的生物组织样本和众多专业外科医生的优势,进一步参与国际学术交流与合作,积极投身国际临床研究并扩大我国在世界上的学术影响力;(3)开展更多多中心前瞻性随机对照试验,以进一步提高我国胃癌外科治疗临床指南、规范和专家共识的科学性;(4)进一步提高多学科团队(MDT)模式的效能,以真正发挥各学科在解决一些疑难病例中的作用;(5)在患者外科治疗方面,应继续推进微创手术、合理围手术期治疗、精细化技术操作、根治性切除,并进一步完善手术质量控制系统,旨在同时实现延长胃癌患者生存时间和提高其生活质量这两个目标。